Horizon Europe
Share this page
LUMC researchers are actively involved in many Horizon2020 (2014-2020) and Horizon Europe (2021-2027) research projects. Here we highlight the ongoing collaborative Horizon Europe projects which are coordinated by LUMC researchers. These projects illustrate LUMC’s leading role in research and innovation in Europe.
Ongoing collaborative Horizon Europe projects coordinated by LUMC researchers
Horizon Europe – Health 2023: PANVIPREP
Developing broad-spectrum antiviral drugs for pandemic preparedness (PANVIPREP)
LUMC PI: Prof. Eric Snijder, PhP
Leiden University Center for Infectious Diseases
- HORIZON-HLTH-2023-DISEASE-03-04 (Research and Innovation Action)
- EC contribution for total project: € 7.999.298
- EC contribution to LUMC: € 1.204.304
- Start date: 01 January 2024 – End date: 31 December 2027
Abstract:
Antiviral drugs will be key in the management of future virus outbreaks. For each virus family with epidemic/pandemic potential, stockpiles of potent drugs are needed that can be deployed
Horizon Europe – Health 2022: WORMVACS2.0
Innovations for vaccines against helminth infections (WORMVACS2.0)
LUMC PI: Prof. Ron Hokke, PhD
Leiden University Center for Infectious Diseases
- HORIZON-HLTH-2022-DISEASE-06-03-two-stage (Research and Innovation Action)
- EC contribution for total project: € 6.881.714
- EC contribution to LUMC: € 2.500.554
- Start date: 01 September 2023 – End date: 30 August 2028
Abstract: Infections with parasitic worms (helminths) continue to cause a massive global health burden. Yet, effective
The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development
Horizon Europe – European Innovation Council 2022: BREATH-SENSE
Miniaturized plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbations.
LUMC PI: Jiska Aardoom, PhD
Dept. Public Health and Primary Care
- HORIZON-EIC-2022-PATHFINDERCHALLENGES-01
- EC contribution for total project: € 3.505.325
- EC contribution to LUMC: € 589.660
- Start date: 01-11-2023 – End date: 30-04-2027
Abstract:
Patients suffering from Chronic Obstructive Pulmonary disease (COPD) suffer from persistent airway obstruction causing
The Breath-Sense consortium aims to develop the first-ever hand-held breathalyzer for non-invasive detection of breath
With this digital biomarker-based monitoring solution, patients and clinicians will benefit from reliable and timely prediction of
Ultimately, the breathalyzer technology is a platform technology that can be applicable for a wide range of respiratory and
Read more: LUMC press release
Horizon Europe – Health 2022: SPIDeRR
Stratification of Patients using advanced Integrative modeling of Data Routinely acquired for diagnosing Rheumatic complaints.
LUMC PI: Rachel Knevel, PhD
Department of Rheumatology
• HORIZON-HLTH-2022-TOOL-12-01-two-stage (Research and Innovation Action)
• EC contribution for total project: €5.494.750
• EC contribution to LUMC: €1.240.300
• Start date: 01-05-2023 – End date: 30-04-2028
Abstract:
Globally 1.71 billion people have musculoskeletal symptoms, the leading contributor to disability. Early disease stratification is important to ensure appropriate care (most suited healthcare provider and best treatment choice). Currently the patient journey to diagnosis and effective treatment is long and inefficient, resulting in persistent disease burden and economical loss. This is due to insufficiently understood relations disease causes and similarities in symptoms between diseases, insufficiently distinguishing tests, trial and error approach in initial treatment.
SPIDeRR aims to disentangle the real-life complexity of early diagnosis of rheumatic diseases by considering the complete web of factors influencing patients’ symptoms. SPIDeRR’s approach will go well beyond the state-of-the-art in the following ways:
- By identifying different disease groups, requiring different therapies, amongst patients with similar symptoms in contrast to the traditional approach aiming to only capture one disease early.
- By integrating all relevant data dimensions from every healthcare level (primary and secondary care and patients seeking advice online).
- By translating and applying machine learning techniques from the “omics” field to clinical patient data, which will result in new pipelines for translational data science
SPIDERR will deliver three clinical models
- a symptom checker for patients
- a decision support tool for (primary) care providers providing guiding additional examination and referral decisions
- a patient-patient similarity network to optimise diagnostic groups in rheumatology and support treatment decision
To achieve this we additionally deliver solutions for data integration and shared analyses though GDPR compliant digital research environment and federated learning pipelines.
Finally we will test the acceptability of the models through stakeholders studies and provide an implementation scene tailored to current healthcare in Europe.
Horizon Europe – Health 2022: FRESHAIR4LIFE
Implementation research on the tailored, multidisciplinary NCD prevention package FRESHAIR4LIFE: Targeting tobacco and air
LUMC PI: Rianne van der Kleij, PhD
Department of Public Health and Primary Care
• Horizon Europe call: HORIZON-HLTH-2022-DISEASE-07-03 (Research and Innovation Action)
• EC contribution for total project: €2.149.813
• EC contribution to LUMC: €407.000
• Start date: 01-01-2023 – End date: 31-12-2026
Abstract:
Non-communicable diseases (NCDs) are responsible for 74 % of all deaths worldwide. We know how to mitigate specific
EU4Health programme - 2021: PCM4EU
Personalised Cancer Medicine for all EU citizens
LUMC PI: Prof. Hans Gelderblom, PhD
Department of Medical Oncology
• EU4Health call: EU4H-2021-PJ-15 (Action grant)
• EC contribution for total project: €2.943.458
• EC contribution to LUMC: €568.761
• Start date: 01-01-2023 - End date: 31-12-2024
Abstract:
Precision Cancer Medicine for Europe (PCM4EU) is a Europe’s Beating Cancer Plan project funded under the EU4Health program with partners from 15 countries across Europe. PCM4EU's goal is to facilitate the implementation of molecular cancer diagnostics for precision oncology such as DRUP-like clinical trials. The project contains six work packages (WPs): WP2 is about mapping and facilitating use of molecular cancer diagnostics and WP3 is about precision oncology and promoting and help starting more national DRUP-like clinical trials in European countries. WP4 is focusing on implementing precision oncology and standards for use in diagnostics and molecular tumour boards (MTBs) in European countries. Furthermore, WP5 is about equitable and cross-border access whereas WP6 is focusing on training of the next generation of oncologists. PCM4EU has also incorporated a patient engagement strategy to ensure access to molecular-based clinical trials and will build a data aggregation platform.
Horizon Europe – HEALTH 2021: Label2Enable
Adopting ISO 82304-2 and a trusted EU mHealth label for a single market that enables patients, citizens, health professionals, systems, and authorities to benefit from a wide range of useful apps. (Label2Enable).
LUMC PI: Petra Hoogendoorn
Department of Public Health and Primary Care / National eHealth Living Lab (NeLL)
- Horizon Europe call: HORIZON-HLTH-2021-IND-07-03 (Coordination and Support Action)
- EC contribution to total project: €1.999.957
- EC contribution to LUMC: €710.957
- Start date: 01-05-2022 – End date: 30-04-2024
Abstract:
There is a growing recognition that health and wellness apps need to play a much stronger role in health care systems, self-care
Horizon Europe – HEALTH 2021: SERENITY
Towards cancer patient empowerment for optimal use of antithrombotic therapy at the end of life (SERENITY)
LUMC PI: Prof. Erik Klok, PhD
Department of Internal Medicine – division of Thrombosis and Haemostasis
- Horizon Europe call: HORIZON-HLTH-2021-DISEASE-04-01 (Research and Innovation Action)
- EC contribution to total project: €4.483.532
- EC contribution to LUMC: €1.726.107
- Start date: 01-10-2022 – End date: 30-09-2027
Abstract:
Antithrombotic therapy (ATT) has negligible positive effects on the wellbeing of terminal cancer patients. However, ATT is often